Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes
Ana Romero; Gemma Llauradó; José-Miguel González-Clemente;
Endocrinol Diabetes Nutr. 2021;68:741-50
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]
Juan Pedro-Botet; Vivencio Barrios; Víctor Sánchez-Margalet; Juan Tamargo; Francisco Arrieta; José Mª Gámez; José Antonio Gimeno-Orna; Carlos Escobar; Juan José Gómez-Doblas; Antonio Pérez;
Endocrinol Diabetes Nutr. 2023;70 Supl 1:51-62
Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study
Felipe Pardo Lozano; Arantxa Rubio Marcos; Rosa Casañ Fernández; Amparo Bartual Rodrigo; Sergio Martínez-Hervás; Francisco Javier Ampudia-Blasco;
Endocrinol Diabetes Nutr. 2025;72: